Novonesis stock trades steady as integration focus follows solid 2024 earnings

Novonesis stock reflects the biotech group’s solid 2024 earnings and ongoing integration of Novozymes and Chr Hansen, with investors watching margin progress and growth in biosolutions.

Novonesis stock, issued by the Danish biosolutions group Novonesis A/S (ISIN DK0060336014), sits against a backdrop of solid 2024 earnings and ongoing integration of the former Novozymes and Chr Hansen businesses, with investors closely following revenue growth and margins across its biosolutions portfolio. According to Novonesis' 2024 annual reporting dated 30 January 2025, the combined group delivered multi-billion Danish krone revenue and healthy profitability, underlining its position as a major player in industrial enzymes, cultures, and other biosolutions.

Revenue up double digits in 2024

According to Novonesis' investor materials for fiscal 2024, the newly formed group reported around DKK 22.0 billion of revenue in 2024, a clear step up from the pre-merger scale of the separate Novozymes and Chr Hansen entities. The company highlighted that on a pro forma basis, underlying organic revenue growth was in the high single-digit range compared to 2023, illustrating that key application areas such as household care, food cultures, and bioenergy continued to expand. In addition, Novonesis pointed out that the integration of the two legacy groups allowed it to present unified segment reporting, giving investors a clearer view of biosolutions demand across industries.

Within that revenue base, Novonesis described strong demand in food and beverage applications, where cultures and enzymes support dairy, baking, and fermentation processes. As summarized in the same 2024 materials, household care and industrial biosolutions also contributed meaningfully, supported by enzymes that help detergents clean effectively at lower temperatures and formulations that can reduce resource use for customers. This breadth of end markets provides a buffer against individual sector swings and makes the revenue line a key anchor for investor analysis.

Operating profit and margin resilience

Profitability remains central to the Novonesis investment case. In its 2024 reporting, Novonesis indicated that the combined group delivered an operating profit (EBIT) of roughly DKK 5.0 billion, supported by efficiency measures and continued focus on high-value applications. Based on the same investor information, this translated into an EBIT margin in the low-to-mid twenties in percent terms, broadly consistent with historic levels for Novozymes and Chr Hansen and demonstrating margin resilience despite integration costs. The company explained that synergies from the merger, including streamlined R&D and administrative structures, should support margins over time even as it invests in growth initiatives.

Novonesis' materials for 2024 also emphasized cash generation, highlighting that free cash flow after investments remained robust thanks to the group’s asset-light model. While exact figures varied between reported and pro forma views, the company showed that its ability to convert profit into cash supported its capacity to fund innovation and potential shareholder distributions. For investors, the combination of a mid-twenties EBIT margin and healthy cash conversion underlines the quality of the underlying biosolutions franchise.

Guidance for 2025 and integration priorities

Looking ahead, Novonesis provided guidance for fiscal 2025 in its early 2025 communications to the market. The group indicated that it expects organic revenue growth in the mid single-digit to high single-digit percent range for 2025, building on the 2024 base and assuming continued demand in food, household care, and industrial applications. It also suggested that the EBIT margin should remain in the low-to-mid twenties, reflecting both synergy realization and ongoing investment in innovation and commercial capabilities. This outlook illustrates management’s confidence that the combined portfolio can deliver sustainable growth and profitability.

At the same time, Novonesis described integration priorities that matter for investors. The company emphasized aligning R&D pipelines across the former Novozymes and Chr Hansen teams, harmonizing manufacturing and supply chains, and creating unified commercial structures to serve global customers more effectively. These steps are designed to capture merger synergies while preserving the scientific and commercial strengths that each legacy company brought to the combination. As integration advances, investors are likely to scrutinize whether revenue synergies and cost efficiencies translate into improved margins and cash generation compared with the pre-merger baseline.

Market valuation and share performance context

Novonesis shares are listed on Nasdaq Copenhagen, giving the company access to a broad Nordic and international investor base. Based on recent Nordic market data as of early 2025, Novonesis' market capitalization has been in the tens of billions of Danish krone, placing it among the more sizeable Danish-listed industrial and biotech-related names. This valuation reflects the market’s view of the long-term potential for biosolutions, where enzymes, cultures, and related technologies can support customers in decarbonization, resource efficiency, and product innovation.

In this context, Novonesis stock trades as a lever on both earnings delivery and strategic progress. Investor attention often focuses on how the share price compares with historical levels for the former Novozymes and Chr Hansen entities, as well as with Nordic peers in specialty chemicals and life sciences. When margins and growth hold near the guided ranges, the market may be more inclined to recognize the value of the merged platform. Conversely, any deviation from guidance or slower-than-expected integration benefits could weigh on sentiment, underscoring the importance of consistent execution.

Bioprotein and enzyme solutions

Novonesis is best known for its broad range of enzyme and microbial solutions, many of which originated in the Novozymes and Chr Hansen portfolios. These products are used in applications spanning food and beverages, household care, bioenergy, agriculture, and industrial processes. For example, in dairy and other fermented foods, cultures developed by the legacy Chr Hansen business help shape taste, texture, and shelf life, while enzymes improve processing efficiency and product consistency. In detergents, enzymes from the Novozymes heritage allow effective cleaning at lower temperatures, reducing energy use and supporting more sustainable consumer behavior.

In agriculture and animal health, Novonesis also offers microbial solutions designed to support plant growth and animal gut health, which can help reduce the need for antibiotics and chemical inputs. The companys biosolutions capabilities are rooted in decades of research and development, with scientists working to identify and optimize microorganisms and enzymes that can deliver specific functional benefits. This innovation engine is a key asset for the group and underpins its long-term growth narrative, as customers increasingly look for ways to improve performance and sustainability simultaneously.

Novonesis stock on Nasdaq Copenhagen

Novonesis stock is traded on Nasdaq Copenhagen in Danish krone, giving investors exposure to a global biosolutions leader through a Nordic listing. The shares reflect the integration of Novozymes and Chr Hansen into a single entity focused on biosolutions, biotechnology, and industrial applications. For investors, the stock offers a way to participate in trends such as sustainable agriculture, low-temperature washing, and food innovation, all of which rely on tailored enzymes and microbial cultures.

As of early 2025, Novonesis' market capitalization in DKK terms illustrates the scale of the opportunity the market perceives in biosolutions, even as the group works through the detailed operational and strategic steps of integration. The trading dynamics on Nasdaq Copenhagen also place Novonesis alongside other significant Danish industrial and healthcare names, contributing to index composition and regional investor portfolios.

Novonesis at a glance

• Company: Novonesis A/S
• ISIN: DK0060336014
• Ticker: CPH: NVNS
• Trading venue: Nasdaq Copenhagen
• Market capitalization: Tens of billions DKK (as of early 2025)
• Sector / Industry: Biotechnology / Biosolutions
• Index membership: Included in key Danish equity indices